These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 1581537)
1. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Rettie AE; Korzekwa KR; Kunze KL; Lawrence RF; Eddy AC; Aoyama T; Gelboin HV; Gonzalez FJ; Trager WF Chem Res Toxicol; 1992; 5(1):54-9. PubMed ID: 1581537 [TBL] [Abstract][Full Text] [Related]
2. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
3. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744 [TBL] [Abstract][Full Text] [Related]
4. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. Zhang ZY; Kerr J; Wexler RS; Li HY; Robinson AJ; Harlow PP; Kaminsky LS Thromb Res; 1997 Nov; 88(4):389-98. PubMed ID: 9526963 [TBL] [Abstract][Full Text] [Related]
5. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Kunze KL; Wienkers LC; Thummel KE; Trager WF Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390 [TBL] [Abstract][Full Text] [Related]
7. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid. Taguchi K; Konishi T; Nishikawa H; Kitamura S Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450 [TBL] [Abstract][Full Text] [Related]
8. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
9. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015 [TBL] [Abstract][Full Text] [Related]
10. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Tracy TS; Rosenbluth BW; Wrighton SA; Gonzalez FJ; Korzekwa KR Biochem Pharmacol; 1995 May; 49(9):1269-75. PubMed ID: 7763308 [TBL] [Abstract][Full Text] [Related]
11. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Kunze KL; Eddy AC; Gibaldi M; Trager WF Chirality; 1991; 3(1):24-9. PubMed ID: 2039681 [TBL] [Abstract][Full Text] [Related]
12. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Yamazaki H; Shimada T Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296 [TBL] [Abstract][Full Text] [Related]
13. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Thijssen HH; Flinois JP; Beaune PH Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154 [TBL] [Abstract][Full Text] [Related]
14. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Yamazaki H; Shimada T Biochem Pharmacol; 1997 Dec; 54(11):1195-203. PubMed ID: 9416970 [TBL] [Abstract][Full Text] [Related]
15. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587 [TBL] [Abstract][Full Text] [Related]
16. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590 [TBL] [Abstract][Full Text] [Related]
17. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Hemeryck A; De Vriendt C; Belpaire FM Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756 [TBL] [Abstract][Full Text] [Related]
19. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Miyazawa M; Shindo M; Shimada T Drug Metab Dispos; 2002 May; 30(5):602-7. PubMed ID: 11950794 [TBL] [Abstract][Full Text] [Related]